BCCA - Vancouver

Futó vizsgálatok

• Toboroz

  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

  NCT07341191· 2. fázis· Forrás

• Toboroz

  STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

  NCT06880523· 2. fázis· Forrás

• Toboroz

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· 3. fázis· Forrás

• Toboroz

  LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

  NCT06623461· 2. fázis· Forrás

• Toboroz

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· 3. fázis· Forrás

• Toboroz

  Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

  NCT06182774· 3. fázis· Forrás

• Toboroz

  Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

  NCT05601440· 2. fázis· Forrás

• Toboroz

  Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

  NCT05371808· Forrás

• Toboroz

  Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  NCT05640999· 2. fázis· Forrás

• Toboroz

  Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

  NCT05180097· 2. fázis· Forrás

• Toboroz

  Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

  NCT04918186· 2. fázis· Forrás

• Fut, nem toboroz

  Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

  NCT04161248· Korai 1. fázis· Forrás

• Fut, nem toboroz

  Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

  NCT04093167· 2/3. fázis· Forrás

• Toboroz

  Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

  NCT03297606· 2. fázis· Forrás

• Toboroz

  Duration of Anti-PD-1 Therapy in Metastatic Melanoma

  NCT02821013· 3. fázis· Forrás

• Fut, nem toboroz

  Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

  NCT02436707· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Melanóma2 toboroz
• Mielóma multiplex2 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyermekkori daganatok1 toboroz
• Hodgkin-limfóma1 toboroz
• Köpenysejtes limfóma1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhtestrák1 toboroz
• Petefészekrák1 toboroz
• Prosztatarák1 toboroz

Kutatók

Ide még nem kötődik kutató.